The <i>Bim</i> deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer
Mingchuan Zhao(Tongji University), Fred R. Hirsch(Tisch Hospital), Shengxiang Ren(Tongji University), Yishi Zhang(Children's Hospital of Chongqing Medical University), Ningning Cheng(Tongji University), Fei Zhou(Shanghai University), Jiayu Li(Zhejiang Chinese Medical University), Chao Zhao(Tongji University), Weijing Cai(Hebei Medical University), Caicun Zhou(Tongji University), Xuefei Li(Harbin Medical University), Ruixin Ren(Tongji University)
Cited by 87
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705